Ayala Pharmaceuticals Inc. (AYLA) News
Filter AYLA News Items
AYLA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest AYLA News From Around the Web
Below are the latest news stories about AYALA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AYLA as an investment opportunity.
Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual MeetingREHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today is announcing a poster presentation highlighting interim results from the Phase 2 segment / Part A of the RINGSIDE Pivotal Phase 2/3 clinical trial in desmoid tumors at the Connective Tissue Oncology Society (C |
Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid TumorsREHOVOT, Israel and WILMINGTON, Del., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today announced that the first patient has been dosed in Part B of RINGSIDE, the Phase 3 randomized segment of the trial evaluating AL102 in desmoid tumors. AL102 is a potent, selective, oral gamma-secretase inhibito |
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Lags Revenue EstimatesAyala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of -20% and 88.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateEntered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject to approval by Ayala’s shareholders and the satisfaction of customary closing conditions Interim positive data from Part A of the RINGSIDE study presented at ESMO demonstrated substantial anti-tumor activity for AL102 as monotherapy and supports continued development AL102 granted Fast Track designation by U.S. FDA for the treatment of progressing desmoid tumors REHOVOT, Israel |
Ayala Pharmaceuticals and Advaxis Agree To Combine, Expect Uplisting On NASDAQAyala Pharmaceuticals Inc (NASDAQ: AYLA) and Advaxis Inc (OTC: ADXS) have announced a merger agreement. The merger would result in a combined company focusing predominantly on developing and commercializing Ayala's lead program AL102 to treat desmoid tumors and Advaxis's candidate ADXS-504 in development for prostate cancer. Ayala's lead candidate, AL102, is currently being investigated in the Phase 2/3 RINGSIDE study in desmoid tumors. The combined company has the cash to advance the combined p |
Cancer treatment developers Ayala Pharmaceuticals and Advaxis to mergeIsrael-based Ayala Pharmaceuticals, which has its U.S. headquarters in Wilmington, entered into a merger agreement Wednesday with Advaxis Inc. in what would be a union of two companies focused on developing therapies targeting cancer. The proposed all-stock deal calls for Ayala (NASDAQ: AYLA) shareholders to own 62.5% of the combined company and shareholders of Monmouth Junction, New Jersey-based Advaxis (OTCQX: ADXS) to own the remaining 32.5%. Executives of Advaxis will lead the combined company, which will be based in New Jersey and have offices in Israel where the majority of Ayala's 35 employees are based. |
Ayala Pharmaceuticals and Advaxis Enter into Merger AgreementMerger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmace |
Advaxis and Ayala Pharmaceuticals Enter into Merger AgreementMerger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmace |
Ayala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid TumorsEvent will feature a review of data from part A of the Phase 2/3 RINGSIDE trial of AL102KOLs and management to present on Thursday, October 6th @ 8 AM ET REHOVOT, Israel and WILMINGTON, Del., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today announced that it will host a key opinion leader (KOL) |
Ayala Pharma (NASDAQ:AYLA) Bags Fast Track Status for Desmoid Tumor Candidate3 trial, RINGSIDE, and has shown positive interim results in Part A, Phase 2 segment of the trial. |